Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ThermoDox and MR-HIFU for Pediatric Solid Tumors
NCT02536183Phase 1Terminated
- Start
- Oct 2016
- Primary completion
- Oct 2022
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of doxorubicin in solid tumor (2 arms). Primary endpoints: Maximum Tolerated Dose of LTLD at 3 weeks, Toxicity profile of LTLD up to 18 weeks and 2 more. Started Oct 2016; status: terminated.
02
Drugs
doxorubicin
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02536183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02536183.